Loading clinical trials...
Loading clinical trials...
Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer
Conditions
Interventions
Afatinib
Selumetinib
+1 more
Locations
2
Netherlands
UMC St. Radboud Nijmegen
Nijmegen, Gelderland, Netherlands
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands
Start Date
June 1, 2015
Primary Completion Date
May 1, 2019
Completion Date
December 1, 2019
Last Updated
August 27, 2018
NCT06662786
NCT06663319
NCT05239741
NCT06885697
NCT05770102
NCT04812912
Lead Sponsor
The Netherlands Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions